EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A founder variant in the RYR1 gene is associated with hyperCKemia , myalgia and muscle cramps

Alba Segarra-Casas iD, Pablo Iruzubieta, Solange Kapetanovic, Aurelio Hernández-Laín, Ivonne Jericó, Roberto Fernández-Torrón, Miren Maneiro, Pablo Marco-Moreno iD, M Victoria Zelaya-Huerta, Benjamín Rodríguez-Santiago, Francesc Calafell, Ana Töpf und 5 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.16471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Alba Segarra-Casas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Muscle Cramp, Myalgia, Creatine Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Universidades, Fundacion Jesus De Gangoiti Barrera, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant.

Methods

Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives.

Results

Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non‐specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype.

Conclusion

Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelMuscle CrampMyalgiaCreatine KinaseFounder EffectHumansMaleFemaleAdultMiddle AgedYoung AdultAgedAdolescentMuscle, SkeletalMagnetic Resonance Imaging

Stichwörter der Autor:innen

RYR1‐related myopathiesexercise intolerancehyperCKemiamyalgia

Substanzen

Ryanodine Receptor Calcium Release ChannelRYR1 protein, humanCreatine Kinase

Autor:innen und Institutionen

  • Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Genetics and Microbiology Department, Universitat Autonòma de Barcelona, Bellaterra, Spain.
  • Group of Neuromuscular Diseases, Donostia University Hospital, Biodonostia-Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain.
  • CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain.
  • Faculty of Medicine, University of Deusto, Bilbao, Spain.
  • ALS and Neuromuscular Unit, Department of Neurology, Hospital Universitario Basurto, Bilbao, Spain.

ORCID-Profile: Alba Segarra-Casas, Pablo Marco-Moreno, Lidia Gonzalez-Quereda

Förderung

  • Ministerio de Universidades
  • Fundacion Jesus De Gangoiti Barrera
  • Instituto de Salud Carlos III
  • Eusko Jaurlaritza
  • Limb Girdle Muscular Dystrophy 2i Research Fund
  • CureLGMD2i
  • Sanofi Genzyme
  • Ultragenyx Pharmaceutical

Zitieren

APA

Segarra-Casas, A., Iruzubieta, P., Kapetanovic, S., Hernández-Laín, A., Jericó, I., Fernández-Torrón, R., Maneiro, M., Marco-Moreno, P., Zelaya-Huerta, M. V., Rodríguez-Santiago, B., Calafell, F., Töpf, A., Straub, V., Vallejo-Illarramendi, A., López de Munain, A., Gallano, P., & Gonzalez-Quereda, L. (2025). A founder variant in the RYR1 gene is associated with hyperCKemia , myalgia and muscle cramps. European Journal of Neurology. https://doi.org/10.1111/ene.16471

Vancouver

Segarra-Casas A, Iruzubieta P, Kapetanovic S, Hernández-Laín A, Jericó I, Fernández-Torrón R, et al. A founder variant in the RYR1 gene is associated with hyperCKemia , myalgia and muscle cramps. European Journal of Neurology. 2025. doi:10.1111/ene.16471

BibTeX
@article{SegarraCasas2025,
  author = {Segarra-Casas, Alba and Iruzubieta, Pablo and Kapetanovic, Solange and Hernández-Laín, Aurelio and Jericó, Ivonne and Fernández-Torrón, Roberto and Maneiro, Miren and Marco-Moreno, Pablo and Zelaya-Huerta, M Victoria and Rodríguez-Santiago, Benjamín and Calafell, Francesc and Töpf, Ana and Straub, Volker and Vallejo-Illarramendi, Ainara and López de Munain, Adolfo and Gallano, Pia and Gonzalez-Quereda, Lidia},
  title = {A founder variant in the RYR1 gene is associated with hyperCKemia , myalgia and muscle cramps},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.16471}
}
Kostenlos starten →